RecruitingNCT06607588

Selection of Resistant Mutations to Dolutegravir in PLWH Treated in Mozambique

Selection of Resistant Mutations to Dolutegravir and Associated Drugs in PLWH Treated in Clinical Practice in Chokwé, Mozambique


Sponsor

Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia

Enrollment

200 participants

Start Date

Oct 25, 2024

Study Type

OBSERVATIONAL

Conditions

Summary

The HIV infection not fully controlled, despite being under antiretroviral treatment, could make virus resistance against the antiretroviral treatments, making hardest the well control of HIV infection. The purpose of this research study is to confirm or deny if a not fully good controlled HIV infection could develop virus resistance against antiretroviral drugs that can difficult the good control of the HIV infection.


Eligibility

Min Age: 18 Years

Inclusion Criteria4

  • Patients able to understand and sign the informed consent form.
  • Documented HIV-1 infection.
  • Under the first line TLD for at least 6 months.
  • At least 3 months follow-up with CV \>200c/ml.

Exclusion Criteria5

  • Patients \<18 years of age.
  • Under the first line regime other than TLD.
  • Patients with active neoplastic processes.
  • Patients with active opportunistic diseases.
  • Patients unable to give informed consent.

Interventions

OTHERNot applicable- observational study

Not applicable- observational study


Locations(1)

Hospital Carmelo

Chokwé, Mozambique

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06607588


Related Trials